Last updated on July 2019

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Brief description of study

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD). This study will also evaluate the anti-tumor effect of ASP1951.

Detailed Study Description

This is a dose-escalation and expansion study of ASP1951. The study consists of 3 periods: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify.

The escalation cohorts will evaluate escalating dose levels of ASP1951 in participants with locally advanced (unresectable) or metastatic solid tumor malignancies including but not limited to squamous cell carcinoma of the head and neck, colorectal cancer, prostate cancer and cervical cancer.

For dose expansion, the tumor-specific cohorts will include participants with any tumor types that respond to study drug treatment during dose escalation.

Participants may reinitiate study drug treatment in the optional Re-treatment period after confirmation that the participant meets all the re-treatment eligibility criteria.

After discontinuation of study drug, all participants will complete an end-of-treatment visit, along with 30-day and 90 day safety follow-up visits.

Clinical Study Identifier: NCT03799003

Find a site near you

Start Over

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »